Prostate Cancer Genomic Classifier VL

Adjuvant Treatment for Men with Prostate Cancer with High Risk of Metastasis, the ERADICATE Study - Ashley Ross

Details
In this discussion, Alicia Morgans and Ashley Ross discuss men in the adjuvant setting with the highest risk of prostate cancer metastasis by genomic stratification. They focus their discussion on Decipher molecular testing after prostatectomy and the Phase III ERADICATE study. The ERADICATE trial was presented at this year's ASCO meeting. Biographies: Ashley Ross, MD, Ph.D., Associate Professor,...

Rationale for the Use of Decipher RP Genomic Classifier to Inform Treatment - Ashley Ross

Details
Alicia Morgans and Ashley Ross discuss Decipher RP genomic classifier for prostatectomy specimens, and how to integrate these tests into clinical practice. Decipher is a genomic classifier that looks at the whole genome and expression patterns on that genome. The genomic classifier score is a prognostic score that goes from 0 to 1, and it was first developed to stratify the risk of metastatic prog...

The Use of the Decipher Biopsy Test Prior to Prostatectomy - Ashley Ross

Details
Alicia Morgans and Ashley Ross discuss the Decipher Biopsy genomic risk assessment test and its use prior to prostatectomy. Dr Ross shares how and why he has integrated this genomic risk stratification test into his clinical practice. The use of Decipher allows patients to be risk stratified based upon the genomics of the tumor tissue and physicians can use the results to determine the course of t...

Decipher Biopsy and Decipher for Prostatectomy in Clinical Practice- Ashley Ross

Details
Alicia Morgans and Ashley Ross discuss Decipher testing, both Decipher Biopsy and Decipher for prostatectomy specimens, and how to integrate these tests into standard clinical practice. Decipher is a genomic classifier that looks at the whole genome and expression patterns on that genome. The genomic classifier score is a prognostic score that goes from 0 to 1, and it was first developed to strati...

Treatment of Unfavorable Intermediate Risk Prostate Cancer - Ashley Ross, Jason Hafron, and Katie Murray

Details
Jason Hafron and Katie Murray join Ashley Ross in a conversation on the treatment of unfavorable intermediate-risk prostate cancer and the value of the genomic classifier useful in guiding treatment considerations. Biographies: Jason Hafron, MD, Associate Professor of Urology, The William Beaumont School of Medicine, Oakland University, Director of Robotic Surgery, Beaumont Hospital Royal Oak, Aub...

The Benefit of ADT Treatment Intensification With Radiotherapy in Localized Prostate Cancer – Dan Spratt and Amar Kishan

Details
Daniel Spratt and Amar Kishan discuss a Lancet Oncology publication, on behalf of the MARCAP Consortium, titled "Androgen Deprivation Therapy Use and Duration with Definitive Radiotherapy for Localised Prostate Cancer: An Individual Patient Data Meta-Analysis." Led by Dr. Kishan, this individual patient data meta-analysis of relevant randomized trials aimed to quantify the benefit of various andro...

The Conundrum of Systemic Salvage Therapy at the Time of Salvage Radiation Therapy - Brandon Mahal

Details
Brandon Mahal joins Alicia Morgans to discuss using salvage systemic therapy in the context of salvage radiation therapy for patients who have had a prior prostatectomy. He presented on this topic at the 2022 Advanced Prostate Cancer Consensus Conference (APCCC) Meeting. The major conundrum is what type of ADT, should we be giving ADT, and for how long. Evaluating these topics, Drs. Mahal and Morg...

The Performance of a Genomic Classifier Score in the Phase 3 SAKK 09/10 in Patients with Biochemical Progression - Alan Dal Pra

Details
Alan Dal Pra joins Alicia Morgans in a discussion on the SAKK 09/10 trial presented at the 2021 ASTRO meeting. Dr. Alan Dal Pra highlights the efficacy of very intensive versus less intensive radiation in the biochemical recurrent prostate cancer population. This conversation also touches on Decipher® scores and PSA values in these patients. Biographies: Alan Dal Pra, MD, Assistant Professor and A...

Validation of Performance of the Decipher Biopsy Genomic Classifier in Intermediate-Risk Prostate Cancer: The Phase III Randomized Trial NRG Oncology/RTOG 0126 – Jeff Michalski

Details
Daniel Spratt and Jeff Michalski discuss the pivotal NRG Oncology RTOG 0126 trial from which Dr Michalski is the PI. This phase III randomized NRG/RTOG 0126 trial provides the first validation of the Decipher biopsy genomic classifier in intermediate-risk prostate cancer. Dr. Spratt provides the background on the rationale for the NRG/RTOG 0126 and the results from the RTOG 0126 trial. They discus...

The Impact of Decipher Biopsy Testing on Clinical Outcomes in Localized Prostate Cancer – Randy A. Vince Jr.

Details
Daniel Spratt and Randy Vince discuss the impact of Decipher Biopsy testing on clinical outcomes in localized prostate cancer. This conversation starts off with a background on Decipher Biopsy testing and how it is used for men with prostate cancer. This then transitions into a discussion on the controls and background of how the study was set up. Dr. Vince then discusses some of the main findings...
email news signup